Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Weinberg, Melissa E ^a   Roman, Mark C ^b   Jacob, Peyton ^a   Wen, Michael ^a   Cheung, Polly ^a   Walker, Ulrich A ^c   Mulligan, Kathleen ^a   Schambelan, Morris ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Tampa Bay Analytical Research Inc   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOMAXX; PYRIMIDINE NUCLEOSIDE; RG 2417; TRIACETYLURIDINE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; 2',3',5' TRI O ACETYLURIDINE; 2',3',5'-TRI-O-ACETYLURIDINE; DRUG DERIVATIVE; URIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; MIDDLE AGED; OSMOLARITY; UPREGULATION;

ADULT; BIOLOGICAL AVAILABILITY; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OSMOLAR CONCENTRATION; UP-REGULATION; URIDINE; YOUNG ADULT;

EID: 79951929144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014709     Document Type: Article

References (21)

1. Setzer B, Lebrecht D, Walker UA, (2008) Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 172: 681-90.
2. Connolly GP, Duley JA, (1999) Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci 20: 218-25.
3. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, et al. (2006) Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 11: 25-34.
4. Sommadossi JP, Carlisle R, Schinazi RF, Zhou Z, (1988) Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 32: 997-1001.
5. Keilbaugh SA, Hobbs GA, Simpson MV, (1993) Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Mol Pharmacol 44: 702-6.
6. Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, et al. (2003) Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 8: 463-470.
7. Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, et al. (2002) Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 1587: 133-44.
8. van Groeningen CJ, Peters GJ, Nadal JC, Laurensse E, Pinedo HM, (1991) Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 83: 437-41.
9. Venhoff N, Zilly M, Lebrecht D, Schirmer D, Klinker H, et al. (2005) Uridine pharmacokinetics of Mitocnol, a sugar cane extract. AIDS 19: 739-40.
10. Ashour OM, Naguib FN, el Kouni MH, (1996) 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. Biochem Pharmacol 51: 1601-11.
11. Von Borstel RW, Bamat MK, (May 1989) Acylated uridine and cytidine and uses thereof. patent WO 89/03837.
12. Ashour OM, Naguib FN, Goudgaon NM, Schinazi RF, el Kouni MH, (2000) Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. Cancer Chemother Pharmacol 46: 235-40.
13. King MP, Attardi G, (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246: 500-3.
14. Bodnar AG, Cooper JM, Leonard JV, Schapira AH, (1995) Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochem J 305: 817-22.
15. Linker W, Loffler M, Schneider F, (1985) Uridine, but not cytidine can sustain growth of Ehrlich ascites tumor cells in glucose-deprived medium with altered proliferation kinetics. Eur J Cell Biol 36: 176-81.
16. Kypson J, Hait G, Mathew R, (1978) Effects of uridine on the performance and the metabolism of oxygenated and hypoxic rabbit hearts. J Mol Cell Cardiol 10: 545-65.
17. Walker UA, Langmann P, Miehle N, Zilly M, Klinker H, et al. (2004) Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 8: 1085-6.
18. Sutinen J, Walker UA, Sevastianava K, Klinker H, Hakkinen AM, et al. (2007) Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 12: 97-105.
19. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS, (1998) Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med 158: 2257-64.
20. Shulman GI, (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-6.
21. Maechler P, Wollheim CB, (2001) Mitochondrial function in normal and diabetic beta-cells. Nature 414: 807-12.